Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess the steady-state pharmacokinetics (PK) of efavirenz
(EFV) in human immunodeficiency virus type 1 (HIV-1) infected subjects on stable
antiretroviral regimens containing EFV, and having selected degrees of hepatic impairment or
normal hepatic function.